Itraconazol Arena

Itraconazole, the active ingredient in Itraconazol Arena, is a triazole antifungal presented as a strength/form for oral use. It treats systemic and superficial fungal infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Itraconazol Arena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is employed to manage fungal diseases that affect various organ systems and skin layers.

- Aspergillosis: controls invasive pulmonary infection and reduces fungal burden. - Candidiasis: treats systemic candidemia and deep‑tissue candidal infections. - Blastomycosis: eradicates Blastomyces dermatitidis infection in lungs and disseminated sites. - Histoplasmosis: resolves Histoplasma capsulatum infection, especially in immunocompromised patients. - Dermatophytosis: clears superficial skin infections caused by dermatophytes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional emesis after dosing. - Abdominal pain: discomfort or cramps in the gastrointestinal tract. - Headache: transient mild to moderate headache. - Rash: skin erythema or pruritus. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice, or hepatitis. - Congestive heart failure: fluid retention and reduced cardiac output. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Visual disturbances: blurred vision or photopsia. - Arrhythmias: irregular heart rhythms, especially in patients with pre‑existing cardiac disease. - Severe hypersensitivity: anaphylaxis or angioedema.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Liver function monitoring: check baseline transaminases and repeat periodically. - Cardiac assessment: avoid in patients with existing heart failure or significant arrhythmias. - Drug review: assess for concomitant medications that share CYP3A4 metabolism. - Hypersensitivity check: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Itraconazole interacts with several agents through CYP3A4 inhibition and other pathways.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that markedly reduces itraconazole exposure. - St. John’s wort: herbal inducer leading to sub‑therapeutic levels. - Certain anti‑arrhythmics (e.g., amiodarone): risk of serious cardiac toxicity. - Protease inhibitors (e.g., ritonavir): may cause unpredictable plasma concentrations. - Certain statins (e.g., simvastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Oral contraceptives: reduced efficacy, consider alternative contraception. - Macrolide antibiotics (e.g., erythromycin): may increase itraconazole levels. - Benzodiazepines metabolized by CYP3A4: possible sedation enhancement. - Digoxin: potential increase in serum concentration.